Dr John Delaney | Executive Director, Amgen Biologics Discovery

Dr John Delaney, Executive Director, Amgen Biologics Discovery, Amgen

John leads Amgen’s Biologic Discovery function responsible for identifying large molecule therapeutic candidates in collaboration with all Amgen Therapeutic Areas, including the discovery of fully human antibody therapeutics using the company’s proprietary platform technology. John joined Amgen in 1992, is based at the Amgen San Francisco site, and leads research teams in numerous Amgen locations.  In 2010, John added the site leadership role for Amgen’s Burnaby, British Columbia research facility, managing the company’s significant protein science resources in Canada, and overseeing site administration.
John holds a Bachelor of Science in Zoology from the University of Montana and earned his Ph.D. in the Department of Microbiology at the University of Arizona. He completed his postdoctoral training at the University of Utah’s Department of Cellular, Viral, and Molecular Biology.


European Antibody Congress 2018, Day 2 @ 11:25

Antibody discovery considerations for ImmunoOncology bi-specific molecules

  • Antibody Discovery
  • T-cell Engager modalities
  • Bi-Specific scaffolds
last published: 19/Oct/18 10:35 GMT
last published: 19/Oct/18 10:35 GMT

back to speakers

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October

Sign Up for Event Updates